[1]李金恒.免疫抑制药环孢素治疗药物监测中的实际问题[J].医学研究与战创伤救治(原医学研究生学报),2009,11(04):333-335.

点击复制

免疫抑制药环孢素治疗药物监测中的实际问题()

分享到62.8K

参考文献/References:

[1]Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine[J]. Transplant Proc, 2004,36(2 Suppl): S420-S425.
[2]Takeuchi H, Matsuno N, Senuma K, et al. Evidence of different pharmacokinetics including relationship among AUC, peak, and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter. Why cyclosporine is monitored by C(2) level and tacrolimus by trough level[J]. Biol Pharm Bull, 2008,31(1): 90-94.
[3] Kahan BD. Therapeutic drug moniting of cyclospotine: 20 years of progress[J]. Transplant Proc, 2004,36(9 Suppl): S378-S391.
[4] Karaalp A, Demir D, Goren MZ, et al. Therapeutic drug monitoring of immunosuppressant drugs in Marmara University Hospital[J]. Ther Drug Monit, 2004,26(3): 263-266.
[5]Yano I. Pharmacodynamic monitoring of calcineurin phosphatase activity in transplant patients treated with calcineurin inhibitors[J]. Drug Metab Pharmacokinet, 2008,23(3): 150-157.
[6]Irtan S, Saint Marcoux, F, Rousseau A, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients[J]. Ther Drug Monit, 2007，29(1): 96-102.
[7]Morris RG. Cyclosporin therapeutic drug monitoring. An established service revisited[J]. Clin Biochem Rev, 2003,24(2): 33-46.
[8] Bowers LD. Therapeutic monitoring for cyclosporine: difficul- ties in establishing a therapeutic window[J]. Clin Biochem, 1991,24(1): 81-87.
[9]金惠敏, 沈清瑞, 吴培根, 等. 肾移植术后监测CsA谷浓度的临床价值[J]. 中华肾脏病杂志, 1994， 10(3): 148-151.
[10] 吴笑春, 沈清瑞. 肾移植患者应用环孢素的有效血药浓度范围[J]. 中国医院药学杂志, 2000,20(3): 173-175.
[11]Carstens J. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy[J]. Scand J Urol Nephrol, 2008,42(3): 286-292.
[12]Kalyoncu M, Topaloglu R, Bayrakci U, et al. Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function[J]. Pediatr Transplant, 2006,10(2): 168-171.
[13]Leung CB, Szeto CC, Ho CS, et al. Pharmacokinetic advantages of two-hour post-dose cyclosporin a level for the therapeutic drug monitoring in stable Chinese kidney transplant recipients[J]. Nephron Clin Pract, 2005,99(3): 68-72.
[14]周洪澜, 李路江, 王金国, 等. 肾移植术后检测CsA血药浓度C2和C0对指导CsA合理应用的价值[J]. 吉林大学学报(医学版), 2007， 33(4): 757-758.
[15]闻质红, 赵峻, 张莉蓉, 等. 肾移植术后环孢素A血药浓度C2监测[J]. 郑州大学学报(医学版), 2006,41(6): 1162-1164.
[16]陈鹭颖, 史道华, 曾昭全, 等. 2小时环孢素A血药浓度是预测移植肾排异反应的敏感指标[J]. 中国药学杂志, 2004,39(9): 707-708.
[17]Wang SM, Lai MK, Chueh SC, et al. Optimal C2 concentration of cyclosporin corrected with good efficacy and safety in Asian kidney transplant recipients[J]. Transplant Proc, 2008,40(7): 2243-2244.
[18]Levy G, Thervet E, Lake J, et al. Patient management by Neoral C(2) monitoring: an international consensus statement[J]. Transplatation, 2002,73(9 Suppl): S12-S18.
[19] 李金恒. 临床个体化用药中的药物基因组学考虑[J]. 中国临床药理学与治疗学, 2007，12(4): 361-365.
[20]Anglicheau D, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update[J]. Pharmacogenomics, 2007， 8(7): 835-849.
[21] Thervet E, Anglicheau D, Legendre C, et al. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation[J]. Ther Drug Monit, 2008,30(2): 143-150.
[22]Crettol S, Venetz JP, Fontana M, et al. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients[J]. Ther Drug Monit, 2008,30(6): 689-699.
[23] Hu YF，Qiu W，Liu ZQ，et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation[J]. Clin Exp Pharmacol Physiol，2006,33(11): 1093-1098.
[24] 焦正, 张明, 仲珑瑾, 等. 两种单克隆抗体荧光免疫偏振法测定人全血中环孢素浓度的比较[J]. 中国医院药学杂志, 2006,26(7): 789-791.
[25]Wallemacq PE, Alexandre K. Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and Emit cyclosporine assays[J]. Clin Chem，1999,45(3): 432-435.
[26]Morris RG. Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring[J]. Ther Drug Monit, 2000,22(2): 160-162.

相似文献/References: